Sofregen Medical Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sofregen Medical Inc.
Device/Diagnostics Quarterly Deal Statistics, Q4 2016
Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.
Execs On The Move, January 2017
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Deals Shaping the Medical Industry, December 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.
Pieris Proteolab AG
Pieris ProteoLab was founded in February 2001 to commercialize anticalins, a novel class of antibody mimetics based on a lipocalin scaffold. Due to their molecular architecture, anticalins offer some distinct advantages over antibodies; Pieris will exploit these advantages in developing new drugs for oncology and inflammatory diseases.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.